Tumor associated antigen peptides and use of same as anti-tumor vaccines
    1.
    发明授权
    Tumor associated antigen peptides and use of same as anti-tumor vaccines 失效
    肿瘤相关抗原肽及其与抗肿瘤疫苗的使用

    公开(公告)号:US07960507B2

    公开(公告)日:2011-06-14

    申请号:US12844663

    申请日:2010-07-27

    IPC分类号: C07K16/00

    摘要: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

    摘要翻译: 本发明涉及肿瘤相关抗原(TAA)肽及其使用方法,其编码相同的多核苷酸和与抗肿瘤疫苗相同的细胞。 更具体地说,本发明涉及衍生自Uroplatinin Ia,Ib,II和III,前列腺特异性抗原(PSA),前列腺酸性磷酸酶(PAP)和前列腺特异性膜抗原(PSMA),BA-46(Lactadherin ),粘蛋白(MUC-1)和细胞因子来源的生长因子(CRIPTO-1),以及其与抗肿瘤疫苗的用途预防或治愈膀胱,前列腺,乳腺癌或其他癌症,特别是癌症。 最特别地,本发明涉及可由HLA-A2分子呈递给免疫系统的肿瘤相关抗原肽。

    Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
    4.
    发明授权
    Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines 失效
    肿瘤相关抗原,其肽,以及抗肿瘤疫苗的用途

    公开(公告)号:US07906620B2

    公开(公告)日:2011-03-15

    申请号:US10524787

    申请日:2003-07-28

    摘要: The invention relates to colon and prostate tumor associated antigen peptides obtainable from prostate specific G protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of prostate (STEAP) and proteins encoded by genes found overexpressed in colon carcinoma cells, such as human 1-8D interferon induced transmembrane protein 2. The invention further relates to a polynucleotide encoding the tumor associated antigen peptides and to pharmaceutical compositions, which are preferably anti-tumor vaccine compositions, containing a tumor associated antigen, at least one tumor associated antigen peptide thereof, or encoding polynucleotide thereof as an active ingredient. The pharmaceutical compositions can be administered to a patient in need thereof to treat or inhibit the development of colon or prostate cancer.

    摘要翻译: 本发明涉及从前列腺特异性G蛋白偶联受体(PSGR)获得的结肠和前列腺肿瘤相关的抗原肽,前列腺的六跨膜上皮抗原(STEAP)和由在结肠癌细胞中过表达的基因编码的蛋白质,例如人1 -8D干扰素诱导的跨膜蛋白2.本发明还涉及编码肿瘤相关抗原肽和药物组合物的多核苷酸,其优选为抗肿瘤疫苗组合物,其含有肿瘤相关抗原,至少一种肿瘤相关抗原肽, 或其编码多核苷酸作为活性成分。 可将药物组合物施用于有需要的患者,以治疗或抑制结肠癌或前列腺癌的发生。

    Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
    5.
    发明申请
    Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines 失效
    肿瘤相关抗原,其肽,以及抗肿瘤疫苗的用途

    公开(公告)号:US20060263342A1

    公开(公告)日:2006-11-23

    申请号:US10524787

    申请日:2003-07-28

    摘要: The invention relates to colon and prostate tumor associated antigen peptides obtainable from prostate specific G protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of prostate (STEAP) and proteins encoded by genes found overexpressed in colon carcinoma cells, such as human 1-8D interferon induced transmembrane protein 2. The invention further relates to a polynucleotide encoding the tumor associated antigen peptides and to pharmaceutical compositions, which are preferably anti-tumor vaccine compositions, containing a tumor associated antigen, at least one tumor associated antigen peptide thereof, or encoding polynucleotide thereof as an active ingredient. The pharmaceutical compositions can be administered to a patient in need thereof to treat or inhibit the development of colon or prostate cancer.

    摘要翻译: 本发明涉及从前列腺特异性G蛋白偶联受体(PSGR)获得的结肠和前列腺肿瘤相关的抗原肽,前列腺的六跨膜上皮抗原(STEAP)和由在结肠癌细胞中过表达的基因编码的蛋白质,例如人1 -8D干扰素诱导的跨膜蛋白2.本发明还涉及编码肿瘤相关抗原肽和药物组合物的多核苷酸,其优选为抗肿瘤疫苗组合物,其含有肿瘤相关抗原,至少一种肿瘤相关抗原肽, 或其编码多核苷酸作为活性成分。 可将药物组合物施用于有需要的患者,以治疗或抑制结肠癌或前列腺癌的发生。

    TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES
    6.
    发明申请
    TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES 失效
    肿瘤相关抗原肽及其作为抗肿瘤疫苗的用途

    公开(公告)号:US20090136462A1

    公开(公告)日:2009-05-28

    申请号:US12326675

    申请日:2008-12-02

    IPC分类号: A61K35/12 C07K7/06 A61K38/08

    摘要: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

    摘要翻译: 本发明涉及肿瘤相关抗原(TAA)肽及其使用方法,其编码相同的多核苷酸和与抗肿瘤疫苗相同的细胞。 更具体地说,本发明涉及衍生自Uroplatinin Ia,Ib,II和III,前列腺特异性抗原(PSA),前列腺酸性磷酸酶(PAP)和前列腺特异性膜抗原(PSMA),BA-46(Lactadherin ),粘蛋白(MUC-1)和细胞因子来源的生长因子(CRIPTO-1),以及其与抗肿瘤疫苗的用途预防或治愈膀胱,前列腺,乳腺癌或其他癌症,特别是癌症。 最特别地,本发明涉及可由HLA-A2分子呈递给免疫系统的肿瘤相关抗原肽。

    Tumor associated antigen peptides and use of same as anti-tumor vaccines
    7.
    发明授权
    Tumor associated antigen peptides and use of same as anti-tumor vaccines 失效
    肿瘤相关抗原肽及其与抗肿瘤疫苗的使用

    公开(公告)号:US07795224B2

    公开(公告)日:2010-09-14

    申请号:US12326675

    申请日:2008-12-02

    IPC分类号: A61K38/00

    摘要: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

    摘要翻译: 本发明涉及肿瘤相关抗原(TAA)肽及其使用方法,其编码相同的多核苷酸和与抗肿瘤疫苗相同的细胞。 更具体地说,本发明涉及衍生自Uroplatinin Ia,Ib,II和III,前列腺特异性抗原(PSA),前列腺酸性磷酸酶(PAP)和前列腺特异性膜抗原(PSMA),BA-46(Lactadherin ),粘蛋白(MUC-1)和细胞因子来源的生长因子(CRIPTO-1),以及其与抗肿瘤疫苗的用途预防或治愈膀胱,前列腺,乳腺癌或其他癌症,特别是癌症。 最特别地,本发明涉及可由HLA-A2分子呈递给免疫系统的肿瘤相关抗原肽。

    Tumor associated antigen peptides and use of same as anti-tumor vaccines
    8.
    发明授权
    Tumor associated antigen peptides and use of same as anti-tumor vaccines 失效
    肿瘤相关抗原肽及其与抗肿瘤疫苗的使用

    公开(公告)号:US07531629B2

    公开(公告)日:2009-05-12

    申请号:US11391476

    申请日:2006-03-29

    IPC分类号: C07K14/00 A61K38/00

    摘要: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

    摘要翻译: 本发明涉及肿瘤相关抗原(TAA)肽及其使用方法,其编码相同的多核苷酸和与抗肿瘤疫苗相同的细胞。 更具体地说,本发明涉及衍生自Uroplatinin Ia,Ib,II和III,前列腺特异性抗原(PSA),前列腺酸性磷酸酶(PAP)和前列腺特异性膜抗原(PSMA),BA-46(Lactadherin ),粘蛋白(MUC-1)和细胞因子来源的生长因子(CRIPTO-1),以及其与抗肿瘤疫苗的用途预防或治愈膀胱,前列腺,乳腺癌或其他癌症,特别是癌症。 最特别地,本发明涉及可由HLA-A2分子呈递给免疫系统的肿瘤相关抗原肽。